Plain-English translation of NCT07052669 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a faster radiation schedule (hypofractionated chemoradiotherapy) works as well as or better than the standard radiation schedule for treating locally advanced lung cancer. Both groups will also receive immunotherapy afterward to help the body fight the cancer. The study wants to see which approach works best and is safest for patients.
Standard radiation therapy for advanced lung cancer takes many weeks. Researchers want to know if a shorter schedule could be equally effective or even better, while reducing the burden of treatment on patients.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the faster or standard radiation schedule, each combined with chemotherapy. Both groups will then receive immunotherapy for up to 12 months. You will have regular clinic visits for check-ups, blood tests, and imaging scans to monitor how well the treatment is working and watch for any side effects. The trial will track your health closely throughout treatment and beyond.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
China